OncoMatch/Clinical Trials/NCT06250959
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
Is NCT06250959 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Blinatumomab and Doxorubicin for all, adult.
Treatment: Blinatumomab · Doxorubicin — In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as induction therapy. The clinical remission rate, MRD negative rate and treaty-related adverse reactions were evaluated.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: BCR fusion
Ph-(BCR-ABL1 negative)B-ALL was diagnosed according to WHO diagnostic criteria
Disease stage
Required: Stage NEWLY DIAGNOSED
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Lab requirements
Kidney function
endogenous creatinine clearance ≧30ml/min
Liver function
total bilirubin ≦ 3 times the upper limit of normal; Alanine aminotransferase ≦ 3 times upper limit of normal; Aspartate aminotransferase ≦ 3 times upper limit of normal (except considering leukemia infiltration)
Cardiac function
Patients with grade 2 or higher heart failure excluded
Liver function: total bilirubin ≦ 3 times the upper limit of normal; Alanine aminotransferase ≦ 3 times upper limit of normal; Aspartate aminotransferase ≦ 3 times upper limit of normal (except considering leukemia infiltration); Renal function: endogenous creatinine clearance ≧30ml/min; Patients with grade 2 or higher heart failure excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify